P658 Evolution of disease phenotype, time to biological therapy and medium-, long-term colectomy rates in Ulcerative Colitis patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort. (21st January 2022)

• Record Type: Journal Article
• Authors: Gonczi, L; Lakatos, L; Golovics, P; Pandur, T; David, G; Erdelyi, Z; Szita, I; Lakatos, P L
• Is Part Of: Journal of Crohn's and colitis. Volume 16(2022)Supplement 1
• Page Start: i569
• Page End: i570
• Publication Date: 2022-01-21
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjab232.779
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: The number of prospective population-based studies evaluating the natural disease course and surgical outcomes of ulcerative colitis (UC) are still limited from Eastern Europe. The present study is a continuation of the Veszprem IBD population-based cohort with a follow-up of the incidence and disease course of IBD since 1977. Our aim was to evaluate disease course by examining progression in disease phenotype, time to biological therapy and colectomy rates in a prospective population-based database from Veszprem Province, including incident UC patients diagnosed between January 1, 2007 and December 31, 2018. Methods: Data of 467 incident UC patients were analyzed (male/female: 236/1231; median age at diagnosis: 36 years(y) [IQR: 25–54]). Both in-hospital and outpatient records were collected and comprehensively reviewed at diagnosis and during clinical follow-up. The mean length of follow-up was 8.34y (SD: 3.5). Disease phenotype was evaluated based on the Montreal classification. Probability of medium-, long-term change in disease course and surgical outcomes were analyzed using Kaplan–Meier survival analysis. Results: Disease extension was proctitis (E1), left sided colitis (E2), and extensive colitis (E3) in 22.3%/ 43.9%/ 33.8% of patients at diagnosis. The probability of disease progression into more extensive phenotype was 6.9% (SE:1.2) at 3 years, 8.3% (SE:1.3) at 5 years and 11.3% (SE:1.6) at 10 years. Figure 1. The Probability of receiving biological therapy after diagnosis was 9.9% (SE:1.4) at 3 years, 13.9% (SE:1.6) at 5 years and 17.8% (SE:2.0) at 10 years in this cohort. Overall colectomy rate was 4.1% in the total population at the end of follow-up. The probability of colectomy was 1.5% (SE:0.6) at 1 year, 3.6% (SE:0.9) at 5 years and 4.4% (SE:1.0) at 10 years in Kaplan-Meier analysis. Figure 2. Conclusion: The probability of progression in disease extent was low overall, similar to results from recent pan-European population-based data. (Burisch 2019, JCC ). Medium- and long-term colectomy rates were lower compared to Western European centers, but somewhat higher compared to our previous data from the Veszprem cohort (2002–2006). (Lakatos 2011, IBD).